TNFα and its receptors in psoriatic skin, before and after treatment with etanercept

International Journal of Immunopathology and Pharmacology

Volumn 22, Issue 4, 2009, Pages 961-966

  Caldarola, G ^a   De Simone, C ^a   Carbone, A ^a   Tulli, A ^b   Amerio, P ^b   Feliciani, C ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

Pathogenesis; Psoriasis; Tumor necrosis factor

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; DERMATOLOGICAL AGENT; IMMUNOGLOBULIN G; NONSTEROID ANTIINFLAMMATORY AGENT; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TNFRSF1A PROTEIN, HUMAN; TNFRSF1B PROTEIN, HUMAN; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG EFFECT; DRUG TARGETING; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; TREATMENT DURATION; BIOPSY; CLINICAL TRIAL; DOWN REGULATION; IMMUNOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; SKIN; TIME; TREATMENT OUTCOME;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BIOPSY; DERMATOLOGIC AGENTS; DOWN-REGULATION; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PSORIASIS; RECEPTORS, TUMOR NECROSIS FACTOR; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; SKIN; TIME FACTORS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 76349115811     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200902200411     Document Type: Article

References (14)

1. Baker BS, Swain AF, Fry L, Valdimarsson H. Epidermal T lymphocytes and HLA-DR expression in psoriasis. Br J Derm 1984; 110:555-64.
2. Bos JD, De Rie MA, Teunissen MBM, Piskin G. Psoriasis: dysregulation of innate immunity. Br J Derm 2005; 152:1098-107.
3. De Rie MA, Goedkoop AY, Bos JD. Overview of psoriasis. Derm Therapy 2004; 17:341-9.
4. Kormeili T, Lowe NJ, Yamauchi PS. Psoriasis: immunopathogenesis and evolving immunomodulators and systemic therapies; U.S. experiences. Br J Derm 2004; 151:3-15.
5. Patel T, Gordon KB. Adalimumab: efficacy and safety in psoriasis and rheumatoid arthritis. Derm Therapy 2004; 17:427-31.
6. Schottelius AJG, Moldawer LL, Dinarello CA, et al. Biology of tumor necrosis factor-α: implications for psoriasis. Exp Dermatol 2004; 13:193-222.
7. Sterry □, Barker J, Boehncke WH, et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. Br J Derm 2004; 151:3-17.
8. Mastroianni A, Minutilli E, Mussi A, et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. Br J Derm 2005; 153:531-6.
9. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175:2721-9.
10. Gottlieb AB. Etanercept for the treatment of psoriasis and psoriatic arthritis. Derm therapy 2004; 17:401-8.
11. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003; 349:2014-22.
12. Fredriksson T, Petterson U. Severe psoriasis: oral therapy with a new retinoid. Dermatologica 1978; 157:238-44.
13. Kawaguchi M, Mitsuhashi Y, Kondo S. Overexpression of tumor necrosis factor-α-converting enzyme in psoriasis. Br J Derm 2005; 152:915-9.
14. Lizzul PF, Aphale A, Malaviya R, et al. Differential expression of phosphorylated NF-kappaB/RelA in normal and psoriatic epidermis and downregulation of NF-kappaB in response to treatment with etanercept. J Invest Dermatol 2005; 124:1275-83.